AbTx - Antibody for Therapy

We are Antibody for Therapy (AbTx)

AbTx is a preclinical stage biotech company developing the next generation of oncology treatments to treat incurable cancers.

AbTx is developing tumor-directed immuno-oncology antibody drugs conjugate (ADC).

AbTx platform called Therano-Stick platform^TM is developing mAb innovative enzymatic conjugation.

The Therano-Stick^TM platform unlocks New Frontiers in Medicine to overcome ADC major drawbacks associated with targeting solid tumors by generating antibody Fragment Drug Conjugates (FDCs).

AbTx is developing AbTx101 against undisclosed target for solid tumors, such as Pancreatic cancer with further tranversal indications.

Key Functions of ADCs

Our mission

Immunotherapy based on ADC has shown lately impressive results to treat various cancers

However, there is a crucial need for a novel strategy regarding the development of antibody Fragment- Drug Conjugates (FDCs) such as Fab fragment, ScFv or VHH.

FDCs are associated with suboptimal solid tumor penetration and better control of Fc-mediated toxicity

Our mission is to pioneer the development and advancement of antibody FDC (Fab, scFv and VHH) by using Therano-Stick^TM platform to transform the landscape of targeted therapies.

Innovation & advantages

Therano-Stick^TM principle

Antibody with engineered glutamine tag (Q-Tag) and microbial transglutaminase mediated conjugation.

Thanks to Therano-Stick^TM platform :

Site specific Conjugation : the patented « Q-Tag » sequence insertion allows to precisely defined location of the selected payload on the antibody.

Preservation of Antibody Activity : the Q-tag conjugation preserves the structure and the functional integrity maintaining also the mAb specificity and affinity.

Reduced Heterogeneity: Therano-Stick^TM technology provide a lower heterogeneity compared to chemical methods for ensuring therapeutic consistency as well lower risk of off-target effects.

Improved Stability : Transglutaminase cross-linking occurrs under mild conditions reducing the likelihood of structural changes or degradation of the antibody and the attached drug payload. The covalent bond can’t be cleaved in physiological conditions.

Mab design Versatility : Transglutaminase based methods can be applied to a variety of antibody formats (IgG / FDCs) and/or payloads (drug, radioelements, dyes…). This wide mAb design flexibility associated with different properties tailored to specific therapeutic needs

More appropriate Pharmacokinetics : mTG conjugaison is suitable for FDCs design with optimizing drug exposure and clearance for specific therapeutic needs.

Better penetration for Solid tumor : FDCs are smaller than full-length antibodies, exhibiting therefore higher tissue penetration, with better drug delivery to the target site.

Lower Immunogenicity Risk : Enzymatic methods result in ADCs with lower immunogenicity compared to certain chemical conjugation approaches.

More Eco-Friendly Process : by using biocompatible reagents and conditions, the overall process is more environmentally friendly compared to some chemical conjugation methods that involve harsh chemicals and solvents.

Strengh of Therano-Stick^TM ADC/FDC platform : Exploring the unique advantages that FDCs bring to the table:

Whole mab IgG (ADC)

Full lenght Antibody
150 kDa

Therano-Stick^TM
features

Fab Fragments
50 kDa

ScFv
25 kDa

VHH
15 kDa

Market Needs

Pancreatic cancer is a devastating disease with a high mortality rate and limited treatment options.

One of the reasons that pancreatic cancer is so hard to treat is that tumors are difficult to penetrate, making it challenging to deliver drugs them.

Moving beyond the traditional ADC design, related FDCs are capable of enhancing therapeutic efficacy of ADCs on solid tumors such as pancreatic cancers improving their pharmacokinetics and reducing side effects

FDC are smaller in molecular size than the conventional ADCs and thus, have a better diffuse penetration into tumor tissues

AbTx has identified an undisclosed target abundant enough to serves as good bringing on pancreatic tumor cells.